Baseline characteristics of patients
| Azithromycin | Placebo | |||||
|---|---|---|---|---|---|---|
| Total(n = 40) | Absence ofP aeruginosa infection(n = 31) | P aeruginosa infection(n = 9) | Total(n = 42) | Absence ofP aeruginosa infection(n = 32) | P aeruginosa infection(n = 10) | |
| CFTR, cystic fibrosis transmembrane regulator; BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity | ||||||
| Data are mean (SD) or number (%) unless otherwise indicated. | ||||||
| Mean (SD) age (years) | 10.9 (3.5) | 10.6 (3.4) | 11.8 (3.9) | 11.1 (3.2) | 10.6 (2.8) | 12.6 (3.9) |
| Sex (M/F) | 24/16 | 20/11 | 4/5 | 22/20 | 18/14 | 4/6 |
| CFTR genotype | ||||||
| ΔF508/ΔF508 | 20 | 15 | 5 | 21 | 16 | 5 |
| ΔF508/others | 17 | 13 | 4 | 15 | 13 | 2 |
| Others and unknown | 3 | 3 | 0 | 6 | 3 | 3 |
| Mean (SD) BMI z score | −0.09 (1.36) | −0.06 (1.46) | −0.16 (0.98) | −0.16 (1.30) | −0.14 (1.21) | −0.22 (1.63) |
| Pancreatic insufficiency | 35 | 26 | 9 | 39 | 30 | 9 |
| Mean (SD) pulmonary function | ||||||
| FEV1 (% predicted) | 86.5 (25.9) | 86.0 (26.3) | 88.2 (26.2) | 84.5 (18.4) | 87.7 (19.0) | 74.6 (12.2) |
| FVC (% predicted) | 94.9 (22.5) | 94.9 (23.4) | 94.9 (20.2) | 94.6 (16.7) | 97.0 (17.4) | 87.0 (12.2) |
| Treatment at enrolment | ||||||
| rhDNase | 20 | 12 | 8 | 26 | 20 | 6 |
| Inhaled corticosteroids | 12 | 8 | 4 | 17 | 12 | 5 |
| Inhaled antibiotics | 11 | 5 | 6 | 15 | 6 | 9 |